JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
JNCE
Delisted
JNCE was delisted on the 3rd of May, 2023.
113 hedge funds and large institutions have $285M invested in Jounce Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 34 increasing their positions, 41 reducing their positions, and 20 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
less call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
17% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 41
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
Holders
113
Holding in Top 10
4
Calls
$390K
Puts
$410K
Top Buyers
| 1 | +$12.3M | |
| 2 | +$10.1M | |
| 3 | +$8.5M | |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$4.66M |
| 5 |
CAC
Cowen and Company
New York
|
+$3.9M |
Top Sellers
| 1 | -$11.4M | |
| 2 | -$9.17M | |
| 3 | -$2.82M | |
| 4 |
Goldman Sachs
New York
|
-$2.23M |
| 5 |
Barclays
London,
United Kingdom
|
-$1.76M |